Sirona Biochem Corp V.SBM

New Press Release - SIRONA BIOCHEM Corporate Update April 2024

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (“Sirona” or the “Company”) provides the following update: Dear shareholders,We are pleased to provide an update on our recent milestones and strategic decisions shaping...read article.

[Turtle4]

Nothing new. family and friends can't or don't want to give any more money. The available resources are not even sufficient to produce enough samples for potential partners. The only thing that is important at the moment is the investor. Without it, everything is for nothing. Even the TFC1067 launch will not be nearly enough. Milestones are probably very low (clever howie opted for higher

[tylerreddick]

Howie didn't "opt" for anything, he took what AbbVie offered, like any beggar on the street. And now, the shareholders are paying the price. I don't know what kind of "institution" is going to fund us until we can make some money, but they are going to want a sweetheart deal, and that is going to take a big chunk of the future profits that WE paid for. Having said

[Turtle4]

However, CAD 0.1 is still too high for these institutions. They will probably wait until Howie gives up and grab the patents from the bankruptcy assets.

[tylerreddick]

I am not sure that whatever "institutution" decides to support the company will want shares. They might just take a percentage of future profits, which could be much more lucrative for them. Either way, existing shareholders will have to give up something. But the bottom line? If we don't give up part of our future gains, we will end up with nothing. So if Howie has to give away

[biorun]

I think someone pointed out earlier that it won't take 2 quarters to book revenue. Why?  The sales channel is already in place and the formula will go into the existing line up of one or more products.  The very day that the product is on the shelf, the consumer demand should be at least, if not better than, prior sales volumes, assuming that Allergan made a logical scientific

[forhandlaren]

You might having trouble understanding english? Otherwize your remark is very similar to a Trump-lie. "The available resources are not even sufficient to produce enough samples for potential partners." That's not true. The in-house small scale capacity is limited to potential parter samples. Stay on track!

[tylerreddick]

Your statement isn't true either, read the news release.

[biorun]

Here is the language: Demand for samples is higher than expected, and they're having to "adjust their plans to accomodate this interest". There is only one way to accommodate the is interest - that is to produce more samples! Product Samples   The demand for product samples has arisen earlier in the development phase than expected, prompting us to adjust our plans to

[lscfa]

Licensing GPM to Asia may happen before SL launch early 2025. Licensing should not require Sirona to complete the new clinical trial of formulations with GPM inside scheduled for 2nd half of 2024.

[forhandlaren]

I like the anti-aging transparancy. Don't think it's fair to expect more. Without current management history we should trade well above 40 cents. Came to realize that there's an additional source of cash - licensing fee paid by the subsidiary to the parent company. The vast costs over the years to bring anti-aging to it's current state will provide the company with a base

[tylerreddick]

" Came to realize that there's an additional source of cash - licensing fee paid by the subsidiary to the parent company. " Robbing Peter to pay Paul?